🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06933238
Starting soon Phase 1/2

Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis

NCT06933238 · tracked via the Priya Life Science China tracker
Sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 1/2
Started
2025-04-25
Last updated
2025-04-18

Condition(s) studied

Sepsis AbdominalGastrointestinal DysfunctionTraditional Chinese Medicine

Investigational drug(s) / intervention(s)

Fuzheng Tongfu Jiedu prescription (FZTFJD)Placebo

Fuzheng Tongfu Jiedu prescription (FZTFJD): Fuzheng Tongfu Jiedu prescription (FZTFJD), a kind of Traditional Chinese medicine (TCM).Conventional Western medical treatment in accordance with the "2021 International Guidelines for the Management of Sepsis and Septic Shock." . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers.

Placebo: Fuzheng Tongfu Jiedu prescription plaebo. Conventional Western medical treatment in accordance with the "2021 International Guidelines for the Management of Sepsis and Septic Shock." . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers.

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled trial.

Eligibility

Sex
ALL
Min age
50 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III. 2. 50-90 years old, regardless of gender. 3. Sequential Organ Failure Assessment (SOFA) score ≥ 2. 4. Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours. 5. Voluntary participation with signed informed consent. Exclusion Criteria: 1. ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible. 2. Patients with allergies or allergic constitution to the investigational herbal medications. 3. Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \> 150 kg), trauma, or surgical factors. 4. Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc. 5. History of gastrointestinal surgery. 6. Long-term use of corticosteroids or immunosuppressants. 7. Severe psychiatric disorders or inability to cooperate with trial protocols. 8. Participation in other clinical trials within 30 days. 9. Pregnant or lactating women. 10. Participated in other clinical studies in the past 3 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ethics Committee of Dongzhimen Hospital Beijing Beijing Municipality

More Dongzhimen Hospital, Beijing trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06933238 on ClinicalTrials.gov ↗ ← All trials in China